Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic HER2-Negative Breast Cancer.

Investigator: Hope Rugo, MD
Sponsor: inVentiv Health Clinical, LLC

Location(s): United States


This is a randomized, double-blind, placebo controlled clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who receive treatment with capecitabine in combination with ruxolitinib versus those who receive treatment with capecitabine alone.